News

More and more bacterial pathogens are developing resistance. There is an increasing risk that current drugs will no longer be effective against infectious diseases. Scientists around the world are

Prof. Rolf Müller, the Founding and Scientific Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biotechnology at Saarland University, has

Affecting hundreds of millions of people, chronic hepatitis B is a widespread global health problem for which there is as yet no cure. In a preclinical study involving the German Center for Infection

Researchers of the German Center for Infection Research (DZIF) at the Paul-Ehrlich-Institut (PEI) and Philipps-Universität Marburg used the "recombinant measles virus" vaccine platform to test vaccine

The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct

In a multicentre phase 3 trial, researchers at the MHH have demonstrated the efficacy and safety of the drug Bulevirtide, which prevents Hepatitis D viruses from entering the liver.

Infection with

Antibiotics affect the composition and dynamics of the gut microbiome. Treatment with antibiotics not only leads to a loss of biodiversity of microorganisms, but also often favours the selection of

The drug candidate BTZ-043 has a novel mechanism of action and belongs to a new class of substances. Discovered at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI

It was previously believed that herpesviruses use certain body cells to replicate and other body cells to remain dormant, that is to remain inactive for a longer period of time. This dogma is now

Every year at least 700,000 people die as a result of infection with antibiotic-resistant bacteria—a figure which according to WHO forecasts could rise to ten million people by 2050 without new